Abstract
Extended-infusion ceftolozane-tazobactam treatment at 1.5 g every 8 h was used to treat multidrug-resistant Pseudomonas aeruginosa in a critically ill patient on continuous venovenous hemofiltration. Serum drug concentrations were measured at 1, 4, 5, 6, and 8 h after the start of infusion. Prefilter levels of ceftolozane produced a maximum concentration of drug (Cmax) of 38.57 μg/ml, concentration at the end of the dosing interval (Cmin) of 31.63 μg/ml, time to Cmax (Tmax) of 4 h, area under the concentration-time curve from 0 to 8 h (AUC0-8) of 284.38 μg · h/ml, and a half-life (t1/2) of 30.7 h. The concentrations were eight times the susceptibility breakpoint for the entire dosing interval.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.
MeSH terms
-
Anti-Bacterial Agents / pharmacokinetics*
-
Anti-Bacterial Agents / therapeutic use
-
Cephalosporins / pharmacokinetics*
-
Cephalosporins / therapeutic use*
-
Critical Illness
-
Drug Resistance, Multiple, Bacterial
-
Hemofiltration
-
Humans
-
Intensive Care Units
-
Male
-
Microbial Sensitivity Tests
-
Middle Aged
-
Penicillanic Acid / analogs & derivatives*
-
Penicillanic Acid / pharmacokinetics
-
Penicillanic Acid / therapeutic use
-
Prospective Studies
-
Prosthesis-Related Infections / drug therapy
-
Prosthesis-Related Infections / microbiology
-
Pseudomonas Infections / drug therapy*
-
Pseudomonas aeruginosa / drug effects*
-
Tazobactam
Substances
-
Anti-Bacterial Agents
-
Cephalosporins
-
ceftolozane
-
Penicillanic Acid
-
Tazobactam
Grants and funding
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.